Activation of the Wnt/β-catenin pathway in solid tumors prevents T cells spontaneous activation and infiltration into the tumor microenvironment, increasing resistance to immune checkpoint inhibitor (PD-1 and CTLA4) therapy. Here, CTLA4 is linked to neoplasm.